

type of report	Current report
number	9/2012
company	PHARMENA

Obtaining a patent in USA

The Management Board of PHARMENA S.A. declares that on 16th March 2012, CORTRIA CORPORATION, a subsidiary company of PHARMENA S.A. received notification that US Patent Office made a decision on granting patent to application no. 12/690,797. The patent will provide protection for the use of 1-methylnicotinamide (1-MNA) in combination with statins in the treatment of lipid profile disorders (by lowering the levels of triglycerides and increasing the level of the so-called "good" cholesterol HDL) on the US market.

This patent is of great importance to the process of commercialisation of the 1-MNA project, due to the fact that American market constitutes ca. 45% of the world market value of dyslipidemia, which was estimated at 42 billion USD in 2012. Dyslipidemia is a disease characterized by lipid profile disorders. Statins are medications that lower the levels of lipoproteins, in particular total cholesterol, LDL lipoproteins, VLDL lipoproteins. Potentially, 1-MNA in combination with statins may provide complete treatment, through correction of all lipid profile parameters.

The information is made public due to the fact that it may influence the asset valuation of PHARMENA S.A. in the form of patent application described in the report, which CORTRIA CORPORATION (a subsidiary company of PHARMENA S.A.) possesses rights to, as well as because of participation in potential revenue resulting from commercialisation of the aforementioned patent application.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1).

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board